Skip to main content

Expert opinion

11-01-2019 | Psoriatic arthritis | Editorial | Article

Screening psoriasis patients for development of psoriatic arthritis

Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.

Vinod Chandran

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

Eoin Feeney

18-10-2018 | Microbiome | Editorial | Article

Why every rheumatologist should understand the microbiome

James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.

James T Rosenbaum, Mark J Asquith

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

NM Wulffraat, AM de Groot, EES Nieuwenhuis

16-10-2018 | Pregnancy | Editorial | Article

Planning and managing pregnancy in lupus patients

Megan Clowse discusses the importance of planning pregnancy in patients with lupus to avoid high-risk pregnancy, and outlines strategies to manage active lupus during pregnancy.

Megan EB Clowse

10-10-2018 | Mental health | Editorial | Article

Why depression and anxiety matter in patients with inflammatory arthritis

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

Susan Bartlett

27-09-2018 | Fibromyalgia | Editorial | Article

Treatment and outcomes of pediatric fibromyalgia: More than resolving pain

David Sherry discusses various pharmacologic and non-pharmacologic treatments for management of pediatric fibromyalgia, and outlines the impact of an interdisciplinary approach on physical function, mental health and pain outcomes in these patients.

David Sherry

20-07-2018 | Granulomatosis with polyangiitis | Editorial | Article

The ongoing evolution of remission maintenance strategies for granulomatosis with polyangiitis

Eric J Gapud and Philip Seo summarize the key milestones in management of severe granulomatosis with polyangiitis, and evaluate the possibility of long-term reduced intensity or drug-free remission for some patients.

Eric J. Gapud, Philip Seo

22-05-2018 | Gout | Editorial | Article

Audits on gout management: Far from excellence, but working on it

Editorial Board member Fernando Pérez-Ruiz analyzes recent audits on the management of gout in primary and secondary care, and suggests strategies to improve clinical practice.

Fernando Pérez-Ruiz

22-03-2018 | Biosimilars | Editorial | Article

Biosimilars: The price is not right

Editorial Board member Marc Cohen analyzes the various economic factors influencing the price of biosimilars over recent years in rheumatology, focusing on the United States healthcare system.

Marc D Cohen

21-02-2018 | Gout | Editorial | Article

Gout therapies and cardiovascular risk

Editorial Board member Fernando Pérez-Ruiz highlights recent clinical trials evaluating the effect of febuxostat on risk of cardiovascular comorbidities, and discusses alternative treatments for gout patients with cardiovascular disease.

Fernando Pérez-Ruiz

14-02-2018 | Nursing | Editorial | Article

The role of the clinical nurse specialist/advanced nurse practitioner in rheumatology practice: Past, present and future

Advanced nurse practitioner Patricia Minnock discusses the development of the roles of advanced nurse practitioner and clinical nurse specialist within the field of rheumatology.

Patricia Minnock

19-12-2017 | Medications | Editorial | Article

Managing antirheumatic medication in patients undergoing elective arthroplasty

Editorial Board member Oliver FitzGerald reviews the recent guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty.

Oliver FitzGerald

30-10-2017 | Gout | Editorial | Article

Evolution or revolution in urate-lowering therapies for gout?

Editorial Board member Fernando Pérez-Ruiz reflects on changing concepts in the understanding of gout, and reviews the latest developments in new urate-lowering medications for the management of gout.

Fernando Pérez-Ruiz

24-10-2017 | Rheumatoid arthritis | Editorial | Article

Demise of the triple

Editorial Board member Marc Cohen reviews the use of triple therapy for the treatment of rheumatoid arthritis, and discusses the possible reasons for its underutilization compared with biologic therapies.

Marc D Cohen

16-08-2017 | Juvenile idiopathic arthritis | Editorial | Article

What’s in a name: The complexity of juvenile idiopathic arthritis

The complexity of juvenile idiopathic arthritis is discussed here by Editorial Board member Sangeeta Sule, focusing on how clinical decisions can be better informed in order to provide more precise and personalized treatment options.

Sangeeta Sule

18-07-2017 | Gout | Editorial | Article

The future of gout: Are you ready for it?

Editorial Board member Fernando Pérez-Ruiz discusses the recent increase in gout-related hospitalizations and asks if we are ready for a future of clinical inertia and passivity when it comes to the management of gout.

Fernando Pérez-Ruiz

08-06-2017 | NSAIDs | Editorial | Article

Cardiovascular risk of non-steroidal anti-inflammatory drugs

Editorial Board member Oliver FitzGerald reviews the cardiovascular risk of non-steroidal anti-inflammatory drugs such as celecoxib, naproxen, and ibuprofen in light of results from the PRECISION study.

Oliver FitzGerald

24-05-2017 | Gout | Editorial | Article

Taking gout seriously

Gout is prevalent in developed countries but does not receive the same investment as conditions such as rheumatoid arthritis. Editorial Board member Fernando Pérez-Ruiz suggests that rheumatologists and healthcare providers need to start taking gout seriously.

Fernando Pérez-Ruiz
image credits